Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 2/2018

01-05-2018 | Short Communication

Clinical trial design and recommendations: collectively, we can take them

Author: Julie Babyar

Published in: Clinical and Experimental Medicine | Issue 2/2018

Login to get access

Abstract

There is dynamic opportunity to advance medical research and clinical trial innovation in the USA and throughout the world. Identified problems and solutions in the clinical research and clinical trial enterprise have emerged over recent years. Strategic plans, public reports, expertise panels and international agreements have been produced, and now is the time to move forward collectively. Recommendations should be reviewed, especially because global healthcare can take them. A robust and future medical research enterprise hinges on maximized clinical trial efficiency, both in the USA and abroad.
Literature
1.
2.
Institute of Medicine, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation. Transforming clinical research in the United States: challenges and opportunities: workshop summary. National Academies Press; 2010.
3.
Weisfeld N, English RA, Claiborne AB. Envisioning a transformed clinical trials enterprise in the United States: establishing an Agenda for 2020: Workshop.
4.
Committee on Strategies for Responsible Sharing of Clinical Trial Data, Board on Health Sciences Policy, Institute of Medicine. Sharing clinical trial data: maximizing benefits, minimizing risk. Washington (DC): National Academies Press (US); 2015.
5.
Ayalew K. FDA perspective on international clinical trials.
6.
Rose K, Kummer H. A new ethical challenge for institutional review boards (IRBs)/ethics committees (ECs) in the assessment of pediatric clinical trials. Children. 2015;2(2):198–210.CrossRefPubMedPubMedCentral
7.
Koenig F, Slattery J, Groves T, Lang T, Benjamini Y, Day S, et al. Sharing clinical trial data on patient level: opportunities and challenges. Biom J. 2015;57(1):8–26.CrossRefPubMed
8.
Francer J, Izquierdo JZ, Music T, Narsai K, Nikidis C, Simmonds H, et al. Ethical pharmaceutical promotion and communications worldwide: codes and regulations. Philos Ethics Humanit Med. 2014;29(9):7.CrossRef
9.
Homedes N, Ugalde A. Availability and affordability of new medicines in Latin American countries where pivotal clinical trials were conducted. Bull World Health Organ. 2015;93(10):674–83.CrossRefPubMedPubMedCentral
10.
Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium—the just price. J Clin Oncol. 2013;31(28):3600–4.CrossRefPubMedPubMedCentral
11.
12.
Sun Q, Santoro MA, Meng Q, Liu C, Eggleston K. Pharmaceutical policy in China. Health Aff. 2008;27(4):1042–50.CrossRef
13.
Garuba HA, Kohler JC, Huisman AM. Transparency in Nigeria’s public pharmaceutical sector: perceptions from policy makers. Global Health. 2009;29(5):14.CrossRef
14.
World Medical Association. Declaration of Helsinki. 2001.
15.
Transparency International UK. Corruption in the pharmaceutical industry: diagnosing the challenges. 2016.
16.
17.
Gaitonde R, Oxman AD, Okebukola PO, Rada G. Interventions to reduce corruption in the health sector. Cochrane Database Syst Rev. 2016;16(8):CD008856.
18.
19.
20.
Levett KM, Roberts CL, Simpson JM, Morris JM. Site-specific predictors of successful recruitment to a perinatal clinical trial. Clin Trials. 2014;11(5):584–9.CrossRefPubMed
21.
Leiter A, Sablinski T, Diefenbach M, Foster M, Greenberg A, Holland J, et al. Use of crowdsourcing for cancer clinical trial development. J Natl Cancer Inst. 2014. doi:10.​1093/​jnci/​dju258.PubMed
22.
23.
24.
Tenaerts P, Madre L, Archdeacon P, Califf RM. The clinical trials transformation initiative: innovation through collaboration. Nat Rev Drug Discov. 2014;13(11):797–8.CrossRefPubMed
Metadata
Title
Clinical trial design and recommendations: collectively, we can take them
Author
Julie Babyar
Publication date
01-05-2018
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 2/2018
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-017-0476-z

Other articles of this Issue 2/2018

Clinical and Experimental Medicine 2/2018 Go to the issue

Original Article

Methylation status of IGF2 DMR and LINE1 in leukocyte DNA provides distinct clinicopathological features of gastric cancer patients

Original Article

Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients

Original Article

Increased BATF expression is associated with the severity of liver damage in patients with chronic hepatitis B

Original Article

Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables

Original Article

Xanthine oxidase and uric acid as independent predictors of albuminuria in patients with diabetes mellitus type 2

Original Article

Mediators of angiogenesis and fibrosis in IgG4-related disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits